Document:

QuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 10.1    
    

THIRD AMENDMENT AND CONSENT TO SECOND AMENDED AND RESTATED

CREDIT AGREEMENT AND CONSENT TO INTERCREDITOR AGREEMENT  

        THIRD AMENDMENT AND CONSENT, dated as of January 20, 2004 (this "Consent"), to the Second Amended and
Restated Credit Agreement, dated as of September 30, 2003 (as amended, supplemented or otherwise modified from time to time, the "Credit
Agreement"), by and among General Electric Capital Corporation, as Agent and Lender ("Agent"), Inverness Medical
Innovations, Inc. ("Innovations"), Wampole Laboratories, LLC, Inverness Medical (UK) Holdings Limited, as borrowers
("Borrowers"), the other Credit Parties signatory thereto, Merrill Lynch Capital, a division of Merrill Lynch Business Financial Services Inc.,
as documentation agent and co-syndication agent, UBS Securities LLC, as co-syndication agent, and the lenders signatory thereto from time to time (collectively, the
"Lenders") and Consent to the Intercreditor Agreement (as amended, supplemented or otherwise modified from time to time, the
"Intercreditor Agreement"), dated as of November 14, 2002, among General Electric Capital Corporation, as agent for the lenders from time to time
party to the Senior Credit Agreement (as defined in the Intercreditor Agreement) (in such capacity, "Senior Agent"), the holders of Subordinated
Obligations (as defined in the Intercreditor Agreement) and the credit parties signatory thereto. 

W
I T N E S S E T H 

        WHEREAS,
Borrowers have notified Agent that Innovations intends to consummate the Subordinated Bond Issuance and issue senior subordinated notes in an aggregate principal amount not to
exceed $165,000,000 and to use a portion of the proceeds thereof to, inter alia, repay in full the 9% Subordinated Notes due on or before
September 20, 2008, in the original aggregate principal amount of $9,000,000 (the "9% Subordinated Notes") issued by Innovations to Perry
Partners L.P., Perry Partners International, Inc. and The Ron Zwanziger 2001 Charitable Remainder Trust, including all accrued and unpaid interest thereon and any prepayment premium with
respect thereto (the "9% Subordinated Notes Repayment" and, together with the Subordinated Bond Issuance, the "Subordinated Bond
Transaction"); 

        WHEREAS,
Borrowers have notified Agent that the terms of the Subordinated Bond Issuance shall be on substantially the terms set forth in the Description of the Notes attached hereto as  Exhibit A (the
"Description of the Notes"); 

        WHEREAS,
Borrowers have requested that, (i) Agent and each Lender consent to the Subordinated Bond Issuance, (ii) notwithstanding the restrictions in  Sections 6.3(b) and 6.14 of the Credit Agreement, which would otherwise prohibit the 9% Subordinated
Notes Repayment absent the consent of Agent and the Requisite Lenders, Agent and the Requisite Lenders consent to the 9% Subordinated Notes Repayment and (iii) notwithstanding the restrictions
in Sections 3.1 and 3.4 of the Intercreditor Agreement, which would otherwise prohibit the 9%
Subordinated Notes Repayment absent the consent of Senior Agent, Senior Agent consents to the 9% Subordinated Notes Repayment; and 

        WHEREAS,
in connection with the consent granted herein, the Borrowers, Agent and Lenders have agreed to amend the Credit Agreement on the terms and conditions set forth herein. 

        NOW
THEREFORE, in consideration of the premises and for other good and valuable consideration, the receipt, adequacy and sufficiency of which are hereby acknowledged, the parties hereto
agree as follows: 

        1.    Definitions.    Capitalized terms not otherwise defined herein shall have the meanings ascribed to them in the
Credit Agreement. 

        2.    Amendment to Subordinated Bond Transaction.    As of the Amendment Effective Date (as hereinafter defined),
(i) Agent and each Lender hereby approves the terms of the Subordinated Bond Issuance on substantially the terms set forth in the Description of Notes;  provided, that the Company 

may
increase the aggregate principal amount of the senior subordinated notes issued in the Subordinated Bond Issuance to an amount not to exceed $165,000,000; (ii) notwithstanding the
restrictions in Sections 6.3(b) and 6.14 of the Credit Agreement, which would otherwise prohibit the 9%
Subordinated Notes Repayment absent the consent of Agent and the Requisite Lenders, Agent and the Requisite Lenders hereby consent to the 9% Subordinated Notes Repayment with a portion of the proceeds
of the Subordinated Bond Issuance; (iii) notwithstanding the restrictions in Sections 3.1 and 3.4
of the Intercreditor Agreement, which would otherwise prohibit the 9% Subordinated Notes Repayment absent the consent of Senior Agent, Senior Agent consents to the 9% Subordinated Notes Repayment;  provided, in each case, that (x) the Subordinated Bond Transaction is consummated on or prior to February 27, 2004, (y) the
proceeds of the Subordinated Bond Issuance (other than those expressly permitted hereunder to be and are used for the 9% Subordinated Notes Repayment) are applied as required pursuant to  Section 1.3(b)(v) of the Credit Agreement until the balance of the Loans are reduced to zero (0), all interest on the Loans have been paid in
full and all fees owing to Agent and Lenders have been paid in full, and (z) the application of proceeds described in clause (y) are in an
amount sufficient to, and do, reduce the outstanding amount of the Loans to zero (0), repay all interest on the Loans, and pay all fees owing to Agent and Lenders. 

        3.    Amendment to Credit Agreement.    

        (a)   Section 1.3(c)(i) of the Credit Agreement is amended by deleting the last sentence therein and inserting in
lieu thereof, the sentence "To the extent the Subordinated Debt Documents governing the Subordinated Bond Issuance require that proceeds of Asset Sales (as such term is defined in the Subordinated
Debt Documents governing the notes issued under the Subordinated Bond Issuance) be used to repay the Revolving Loans and permanently reduce the availability of the Revolving Loan Commitments, the
European Revolving Loan Commitment shall be so reduced to the extent the Asset Sale was made by an European Credit Party and the US Revolving Loan Commitment shall be so reduced to the extent the
Asset Sale was made by a US Credit Party." 

        (b)   Section 5.4(d) of the Credit Agreement is amended by inserting at the end thereof, the sentence "Notwithstanding
anything herein to the contrary, key man life insurance policy shall not be required if either the Subordinated Bond Issuance or a Successful Syndication is consummated on or prior to March 31,
2004. In the event neither the Subordinated Bond Issuance nor the Successful Syndication is consummated on or prior to March 31, 2004, US Borrower shall obtained such key man life insurance
policy on or before May 15, 2004." 

        (c)   Clause (f)
of Section 6.14 of the Credit Agreement is deleted in its entirety and the following
clause (f) is inserted in lieu thereof: "(f) the Credit Parties may make cash distributions to Innovations to enable Innovations to pay, and Innovations may pay, regularly scheduled interest
payments on Indebtedness incurred pursuant to the Subordinated Bond Issuance to the extent permitted by Subordinated Debt Documents (including any subordination agreements with respect thereto)
governing the Subordinated Bond Issuance." 

        (d)   Section 8.1(l) is amended by inserting the words "or, for so long as any of the notes issued under the
Subordinated Bond Issuance remain outstanding, any "Change of Control" (as such term is defined in the Subordinated Debt Documents governing the notes issued under the Subordinated Bond Issuance)"
immediately after the term "occurs" appearing therein. 

        4.    Representations and Warranties.    To induce Agent, Senior Agent and the Lenders to enter into this Amendment,
the Credit Parties hereby, jointly and severally, represent and warrant that: 

        (a)   The
execution, delivery and performance by each Credit Party of the Loan Documents to which it is a party and the creation of all Liens provided for therein:
(a) are within such Person's corporate, company or partnership power; (b) have been duly authorized by all necessary corporate, limited liability company or limited partnership action;
(c) do not contravene any provision of such Person's charter, bylaws or equivalent constitutive documents or partnership or operating agreement, as applicable; (d) do not violate any law
or regulation, or any order or decree of any court or Governmental Authority; (e) do not conflict with or result in the breach or 

termination
of, constitute a default under or accelerate or permit the acceleration of any performance required by, any indenture, mortgage, deed of trust, lease, agreement or other instrument to
which such Person is a party or by which such Person or any of its property is bound; (f) do not result in the creation or imposition of any Lien upon any of the property of such Person; and
(g) do not require the Amendment or approval of any Governmental Authority or any other Person. 

        (b)   This
Amendment has been duly executed and delivered by or on behalf of each of the Credit Parties. 

        (c)   This
Amendment constitutes a legal, valid and binding obligation of each of the Credit Parties, enforceable against each of them in accordance with its terms. 

        (d)   No
Default or Event of Default has occurred and is continuing after giving effect to this Amendment. 

        (e)   No
action, claim or proceeding is now pending or, to the knowledge of any Credit Party, threatened against such Credit Party, at law, in equity or otherwise, before any
court, board, commission, agency or instrumentality of any foreign, federal, state, or local government or of any agency or subdivision thereof, or before any arbitrator or panel of arbitrators, which
(a) challenges any Credit Party's right or power to enter into or perform any of its obligations under this Amendment, the Credit Agreement and the other Loan Documents to which it is a party,
or the validity or enforceability of this Amendment, the Credit Agreement or any Loan Document or any action taken thereunder, or (b) has a reasonable risk of being determined adversely to any
Credit Party and that, if so determined, could be reasonably be expected to have a Material Adverse Effect after giving effect to this Amendment. 

        (f)    The
representations and warranties of the Credit Parties contained in the Credit Agreement and each other Loan Document shall be true and correct on and as of the
Amendment Effective Date with the same effect as if such representations and warranties had been made on and as of such date, except that any such representation or warranty which is expressly made
only as of a specified date need be true only as of such date. 

        5.    No Other Amendments/Waivers.    Except as expressly provided herein, (i) the Credit Agreement shall be
unmodified and shall continue to be in full force and effect in accordance with its terms and (ii) this Amendment shall not be deemed a waiver of any term or condition of any Loan Document and
shall not be deemed to prejudice any right or rights which Agent or any Lender may now have or may have in the future under or in connection with any Loan Document or any of the instruments or
agreements referred to therein, as the same may be amended from time to time. 

        6.    Outstanding Indebtedness; Waiver of Claims.    Each of Borrowers and other Credit Parties hereby acknowledges
and agrees that as of December 22, 2003, (a) the aggregate outstanding principal amount of the European Revolving Loan is $22,960,000, (b) the aggregate outstanding principal
amount of the US Revolver Loan is $16,898,797.30, (c) the aggregate outstanding principal amount of the US Term A Loan is $35,075,000, and (d) the aggregate outstanding principal amount
of the US Term B Loan is $40,000,000, and (e) the aggregate outstanding principal amount of the European Term Loan is $9,900,000, and that such principal amount is payable pursuant to the
Credit Agreement without defense, offset, withholding, counterclaim or deduction of any kind. Each Borrower and other Credit Party hereby waives, releases, remises and forever discharges Agent,
Lenders and each other Indemnified Person from any and all claims, suits, actions, investigations, proceedings or demands arising out of or in connection with the Credit Agreement (collectively,
"Claims"), whether based in contract, tort, implied or express warranty, strict liability, criminal or civil statute or common law of any kind or
character, known or unknown, which any Borrower or any other Credit Party ever had, now has or might hereafter have against Agent or Lenders which relates, directly or indirectly, to any acts or
omissions of Agent, Lenders or any other Indemnified Person on or prior to the Amendment Effective Date, provided, that no Borrower nor any other Credit
Party waives any Claim solely to the extent such Claim relates to Agent's or any Lender's gross negligence or willful misconduct. 

        7.    Expenses.    Borrowers hereby reconfirm their obligations pursuant to  Section 11.3 of the Credit Agreement to pay and
reimburse Agent for all reasonable costs and expenses (including, without limitation, reasonable
fees of counsel) incurred in connection with the negotiation, preparation, execution and delivery of this Amendment and all other documents and instruments delivered in connection herewith. 

        8.    Effectiveness.    This Amendment shall become effective as of January 20, 2004 (the
"Amendment Effective Date") only upon satisfaction in full in the judgment of Agent of each of the following conditions: 

        (a)    Amendment.    Agent shall have received four (4) original signature pages to this Amendment, duly
executed and delivered by Agent, Senior Agent, and each Lender and each of the Credit Parties. 

        (b)    Payment of Expenses.    Borrowers shall have paid to Agent all costs, fees and expenses owing and billed as of
the date hereof in connection with this Amendment and the other Loan Documents and due to Agent (including, without limitation, reasonable legal fees and expenses). 

        (c)    Representations and Warranties.    The representations and warranties of or on behalf of each Credit Party in
this Amendment shall be true and correct on and as of the Amendment Effective Date. 

        9.    GOVERNING LAW.    THIS AMENDMENT SHALL BE GOVERNED BY, AND INTERPRETED IN ACCORDANCE WITH, THE LAW OF THE STATE
OF NEW YORK. 

        10.    Counterparts.    This Amendment may be executed by the parties hereto on any number of separate counterparts
and all of said counterparts taken together shall be deemed to constitute one and the same instrument. 

        IN
WITNESS WHEREOF, this Amendment has been duly executed as of the date first written above. 

	 	 	WAMPOLE LABORATORIES, LLC.

INVERNESS MEDICAL (UK) HOLDINGS LIMITED
	

 	
 	

By:	

/s/  ANTHONY J. BERNARDO      
 Name: Anthony J. Bernardo

Title: Duly Authorized Signatory

	 	 	AGENT AND LENDERS
	

 	
 	

GENERAL ELECTRIC CAPITAL

CORPORATION, as Agent and Lender
	

 	
 	

By:	

/s/  ILLEGIBLE      
 Duly Authorized Signatory
	

 	
 	

GENERAL ELECTRIC CAPITAL

CORPORATION, as Senior Agent
	

 	
 	

By:	

/s/  ILLEGIBLE      
 Duly Authorized Signatory
	

 	
 	

MERRILL LYNCH CAPITAL, a division of Merrill Lynch Business Financial Services Inc., as Co-Syndication Agent, Documentation Agent and Lender
	

 	
 	

By:	

/s/  ILLEGIBLE      
 Duly Authorized Signatory
	

 	
 	

UBS SECURITIES LLC, as Co-Syndication Agent
	

 	
 	

By:	

/s/  DAVID A. JUGE, MANAGING DIRECTOR      
 Duly Authorized Signatory
	

 	
 	

By:	

/s/  OLIVER O. TRUMBO II, DIRECTOR      
 Duly Authorized Signatory
	

 	
 	

UBS AG, CAYMAN ISLANDS BRANCH, as a Lender
	

 	
 	

By:	

/s/  WILFRED V. SAINT, ASSOCIATE DIRECTOR      
 Banking Products Services, US

Duly Authorized Signatory
	

 	
 	

By:	

/s/  THOMAS R. SALZANO, DIRECTOR      
 Banking Products Services, US

Duly Authorized Signatory

        The
following Persons are signatories to this Amendment in their capacity as Credit Parties, Grantors, Guarantors, Pledgors and not as Borrowers. 

	 	 	INVERNESS MEDICAL INNOVATIONS, INC.

INVERNESS MEDICAL, INC.

UNIPATH DIAGNOSTICS, INC.

UNIPATH ONLINE, INC.

OSTEX INTERNATIONAL, INC.

INVERNESS MEDICAL INTERNATIONAL

HOLDING CORP.

INVERNESS MEDICAL INTERNATIONAL

HOLDING CORP. II

UNIPATH LIMITED

APPLIED BIOTECH, INC.

FOREFRONT DIAGNOSTICS, INC.

MORPHEUS ACQUISITION CORP.

MORPHEUS ACQUISITION LLC

INVERNESS MEDICAL CANADA INC.—

MEDICALE INVERNESS CANADA INC.

INNOVATIONS RESEARCH LLC
	

 	
 	

By:	

/s/  ANTHONY J. BERNARDO      
 Name: Anthony J. Bernardo

Title: Duly Authorized Signatory
	

 	
 	

ORGENICS INTERNATIONAL HOLDINGS BV

INVERNESS MEDICAL SWITZERLAND GMBH

UNIPATH DIAGNOSTICS GMBH

CAMBRIDGE DIAGNOSTICS IRELAND LIMITED

PREGYMED GMBH

SCANDINAVIAN MICRO BIODEVICES APS
	

 	
 	

By:	

/s/  PAUL T. HEMPEL      
 Name: Paul T. Hempel

Title: Duly Authorized Signatory
	

 	
 	

SELFCARE TECHNOLOGY, INC.
	

 	
 	

By:	

/s/  DUANE L. JAMES      
 Name: Duane L. James

Title: Duly Authorized Signatory

QuickLinks

Exhibit 10.1QuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 10.2    
    

FOURTH AMENDMENT TO SECOND AMENDED AND RESTATED CREDIT

AGREEMENT AND AMENDMENT TO LOAN DOCUMENTS  

        FOURTH AMENDMENT, dated as of February 5, 2004 (this "Amendment"), to the Second Amended and Restated
Credit Agreement, dated as of September 30, 2003 (as amended, supplemented or otherwise modified from time to time, the "Credit Agreement"), by
and among General Electric Capital Corporation, as Agent and Lender ("Agent"), Inverness Medical Innovations, Inc.
("Innovations"), Wampole Laboratories, LLC, and Inverness Medical (UK) Holdings Limited, as borrowers
("Borrowers"), the other Credit Parties signatory thereto, Merrill Lynch Capital, a division of Merrill Lynch Business Financial Services Inc.,
as documentation agent and co-syndication agent, UBS Securities LLC, as co-syndication agent, and the lenders signatory thereto from time to time (collectively, the
"Lenders") and Amendment to the US Guaranty, US Intellectual Property Security Agreement, US Pledge Agreement and US Security Agreement (as such terms
are defined in the Credit Agreement). 

W
I T N E S S E T H 

        WHEREAS,
it is and was the intent of the Agent, Lenders, Borrowers and other Credit Parties to structure the facilities under the Credit Agreement such that no European Credit Party (as
defined in the Credit Agreement prior to giving effect to this Amendment) would guarantee or otherwise provide security for any Obligations owing by any US Credit Party (as defined in the Credit
Agreement prior to giving effect to this Amendment); 

        WHEREAS,
the Borrowers have notified Agent that, for purposes of Section 956 of the IRC, as a result of the limited liability nature of Morpheus Acquisition LLC
("Morpheus LLC") the guaranty by Morpheus LLC of the Obligations owing by US Credit Parties (the "US
Obligations") and other provisions of credit support for the US Obligations given by Morpheus LLC, Inverness Medical Switzerland GmbH will be deemed to have guaranteed and
provided security for the US Obligations; 

        WHEREAS,
the parties desire to amend the Credit Agreement and the Loan Documents to reflect the original intent of all parties and accordingly agree that all such amendments be effective
as of the date of execution thereof; 

        WHEREAS,
Borrowers have requested that the definition of Interest Expense be amended to exclude certain non-cash charges; and 

        WHEREAS,
the Borrowers, Agent and Lenders have agreed to amend the Credit Agreement and the Loan Documents on the terms and conditions set forth herein. 

        NOW
THEREFORE, in consideration of the premises and for other good and valuable consideration, the receipt, adequacy and sufficiency of which are hereby acknowledged, the parties hereto
agree as follows: 

        1.    Definitions.    Capitalized terms not otherwise defined herein shall have the meanings ascribed to them in the
Credit Agreement. 

        2.    Amendment to Section 5.11 of the Credit Agreement.    As of the Amendment Effective Date (as hereinafter
defined), Section 5.11 of the Credit Agreement shall be amended by inserting the following sentence at the beginning thereof: 

        "If
at any time any European Credit Party that is treated for purposes of Section 956 of the IRC as a "controlled foreign corporation, thereafter fails to be treated as a
controlled foreign corporation, then at the request of the Agent or the Requisite Lenders, Innovations shall cause each such European Credit Party to execute and deliver to the Agent (a) a
Guaranty in form and substance reasonably satisfactory to the Agent, guarantying the Obligations of US Borrower hereunder and under the other Loan Documents, and (b) Collateral Documents in
form and substance reasonably satisfactory to Agent, granting to Agent a Lien over such European Credit Party's properties and assets, in each case, 

 

to
the extent such European Credit Party has, or is required to have, entered into a Guaranty or a Collateral Document with respect to the Obligations of the European Credit Parties, and to the extent
such Guaranty or Collateral Document is not prohibited by the law of the jurisdiction of formation of such European Credit Party, and shall cause the pledge of all Stock of such European Credit Party
to Agent to secure all of the Obligations to the extent only a portion of such Stock was previously pledged to Agent to secure the Obligations of US Credit Parties." 

        3.    Amendment to Annex A to the Credit Agreement.    As of the Amendment Effective Date (as hereinafter defined),
Annex A to the Credit Agreement shall be amended by deleting the definitions "European Credit Party", "Interest Expense", "Obligations", "Senior US Leverage Ratio" and "US Credit Party", and inserting
in lieu thereof the following terms respectively: 

        "European Credit Party" means each of European Borrower, Swissco and Orgenics Holdings, Morpheus LLC and each of their respective
Subsidiaries (other than the Excluded European Subsidiaries). 

        "Interest Expense" means, with respect to any Person for any fiscal period, interest expense (whether cash or non-cash) of
such Person determined in accordance with GAAP for the relevant period ended on such date, including, interest expense with respect to any Funded Debt of such Person and interest expense for the
relevant period that has been capitalized on the balance sheet of such Person but excluding all non-cash charges as they relate to the amortization or write-offs of capitalized
financing or debt origination fees or costs. 

        "Obligations" means all loans, advances, debts, liabilities and obligations for the performance of covenants, tasks or duties or for
payment of monetary amounts (whether or not such performance is then required or contingent, or such amounts are liquidated or determinable) owing by any Credit Party to Agent or any Lender, and all
covenants and duties regarding such amounts, of any kind or nature, present or future, whether or not evidenced by any note, agreement or other instrument, arising under the Agreement or any of the
other Loan Documents. This term includes all principal, interest (including all interest that accrues after the commencement of any case or proceeding by or against any Credit Party in bankruptcy,
whether or not allowed in such case or proceeding), Fees, Charges, expenses, attorneys' fees and any other sum chargeable to any Credit Party under the Agreement or any of the other Loan Documents.
Notwithstanding the forgoing, with respect to Morpheus LLC, in its capacity as (i) a Grantor under the US Security Agreement and the US Intellectual Property Security Agreement, (ii) a
Guarantor under the US Guaranty, and (iii) a Pledgor under the US Pledge Agreement, "Obligations" or similar terms under such documents shall mean Obligations of the European Credit Parties and
shall not include Obligations of the US Credit Parties. 

        "Senior US Leverage Ratio" means with respect to all US Credit Parties that are Reporting Credit Parties and Morpheus LLC, the ratio of
(a) the outstanding principal amount of the US Term Loan and the US Revolving Loan on any date of determination to (b) the sum of LTM EBITDA attributable to the US Credit Parties and
Morpheus LLC for the twelve months ending on that date of determination; provided that, for purposes of calculating compliance with the Senior US
Leverage Ratio for such
period, US Borrower may include revenues generated by licenses of US Borrower's Intellectual Property which have been assigned to Swissco in an amount not to exceed $800,000 in the aggregate for such
period. 

        "US Credit Party" means Innovations, US Borrower and each of their respective Domestic Subsidiaries (other than Morpheus LLC and the
Excluded US Subsidiaries). 

        4.    Amendment to Annex F to the Credit Agreement.    Clause (g) to Annex F to the Credit Agreement shall be
amended by inserting the words "and Morpheus LLC, collectively" after the words US Credit Parties that are Reporting Credit Parties in the first sentence thereof. 

2

 

        5.    Amendment to the US Guaranty, US Security Agreement, US Intellectual Property Security Agreement and US Pledge
Agreement.    For the avoidance of doubt, each of the US Guaranty, US Security Agreement, US Intellectual Property Security Agreement and US Pledge Agreement is
hereby amended as of the Amendment Effective Date, to reflect amendments to the terms therein which have the meanings ascribed to them in the Credit Agreement and which are hereby being amended under  Section 3 above. 

        6.    Representations and Warranties.    To induce Agent, Senior Agent and the Lenders to enter into this Amendment,
the Credit Parties hereby, jointly and severally, represent and warrant that: 

        (a)   The
execution, delivery and performance by each Credit Party of the Loan Documents to which it is a party and the creation of all Liens provided for therein:
(a) are within such Person's corporate, company or partnership power; (b) have been duly authorized by all necessary corporate, limited liability company or limited partnership action;
(c) do not contravene any provision of such Person's charter, bylaws or equivalent constitutive documents or partnership or operating agreement, as applicable; (d) do not violate any law
or regulation, or any order or decree of any court or Governmental Authority; (e) do not conflict with or result in the breach or termination of, constitute a default under or accelerate or
permit the acceleration of any performance required by, any indenture, mortgage, deed of trust, lease, agreement or other instrument to which such Person is a party or by which such Person or any of
its property is bound; (f) do not result in the creation or imposition of any Lien upon any of the property of such Person; and (g) do not require the Amendment or approval of any
Governmental Authority or any other Person. 

        (b)   This
Amendment has been duly executed and delivered by or on behalf of each of the Credit Parties. 

        (c)   This
Amendment constitutes a legal, valid and binding obligation of each of the Credit Parties, enforceable against each of them in accordance with its terms. 

        (d)   No
Default or Event of Default has occurred and is continuing after giving effect to this Amendment. 

        (e)   No
action, claim or proceeding is now pending or, to the knowledge of any Credit Party, threatened against such Credit Party, at law, in equity or otherwise, before any
court, board, commission, agency or instrumentality of any foreign, federal, state, or local government or of any agency or subdivision thereof, or before any arbitrator or panel of arbitrators, which
(a) challenges any Credit Party's right or power to enter into or perform any of its obligations under this Amendment, the Credit Agreement and the other Loan Documents to which it is a party,
or the validity or enforceability of this Amendment, the Credit Agreement or any Loan Document or any action taken thereunder, or (b) has a reasonable risk of being determined adversely to any
Credit Party and that, if so determined, could be reasonably be expected to have a Material Adverse Effect after giving effect to this Amendment. 

        (f)    The
representations and warranties of the Credit Parties contained in the Credit Agreement and each other Loan Document shall be true and correct on and as of the date
hereof and as of the Amendment Effective Date with the same effect as if such representations and warranties had been made on and as of such date, except that any such representation or warranty which
is expressly made only as of a specified date need be true only as of such date. 

        (g)   Morpheus
LLC does not own any assets other than (i) equipment with appraised value of approximately $139,800, (ii) receivables valued at approximately
$2,200,000 as of December 31, 2003, and (iii) goodwill. 

3

 

        7.    No Other Amendments/Waivers.    Except as expressly provided herein, (i) the Credit Agreement shall be
unmodified and shall continue to be in full force and effect in accordance with its terms and (ii) this Amendment shall not be deemed a waiver of any term or condition of any Loan Document and
shall not be deemed to prejudice any right or rights which Agent or any Lender may now have or may have in the future under or in connection with any Loan Document or any of the instruments or
agreements referred to therein, as the same may be amended from time to time. 

        8.    Outstanding Indebtedness; Waiver of Claims.    Each of Borrowers and other Credit Parties hereby acknowledges
and agrees that as of February 4, 2004, (a) the aggregate outstanding principal amount of the European Revolving Loan is $22,960,000.01, (b) the aggregate outstanding principal
amount of the
US Revolver Loan is $16,898,797.30, (c) the aggregate outstanding principal amount of the US Term A Loan is $35,075,000.00, and (d) the aggregate outstanding principal amount of the US
Term B Loan is $40,000,000.00, and (e) the aggregate outstanding principal amount of the European Term Loan is $9,875,000.00, and that such principal amount is payable pursuant to the Credit
Agreement without defense, offset, withholding, counterclaim or deduction of any kind. Each Borrower and other Credit Party hereby waives, releases, remises and forever discharges Agent, Lenders and
each other Indemnified Person from any and all claims, suits, actions, investigations, proceedings or demands arising out of or in connection with the Credit Agreement (collectively,
"Claims"), whether based in contract, tort, implied or express warranty, strict liability, criminal or civil statute or common law of any kind or
character, known or unknown, which any Borrower or any other Credit Party ever had, now has or might hereafter have against Agent or Lenders which relates, directly or indirectly, to any acts or
omissions of Agent, Lenders or any other Indemnified Person on or prior to the Amendment Effective Date, provided, that no Borrower nor any other Credit
Party waives any Claim solely to the extent such Claim relates to Agent's or any Lender's gross negligence or willful misconduct. 

        9.    Expenses.    Borrowers hereby reconfirm their obligations pursuant to  Section 11.3 of the Credit Agreement to pay and
reimburse Agent for all reasonable costs and expenses (including, without limitation, reasonable
fees of counsel) incurred in connection with the negotiation, preparation, execution and delivery of this Amendment and all other documents and instruments delivered in connection herewith. 

        10.    Effectiveness.    This Amendment shall become effective as of September 30, 2003 (the
"Amendment Effective Date") only upon satisfaction in full in the judgment of Agent and each Lender of each of the following conditions on or before
February 27, 2004: 

        (a)    Amendment.    Agent shall have received four (4) original signature pages to this Amendment, duly
executed and delivered by Agent, Senior Agent, and each Lender and each of the Credit Parties. 

        (b)    Payment of Expenses.    Borrowers shall have paid to Agent all costs, fees and expenses owing and billed as of
the date hereof in connection with this Amendment and the other Loan Documents and due to Agent (including, without limitation, reasonable legal fees and expenses). 

        (c)    Representations and Warranties.    The representations and warranties of or on behalf of each Credit Party in
this Amendment shall be true and correct on and as of the date hereof. 

        (d)    Subordinated Bond Issuance.    The Subordinated Bond Issuance and the related transactions with respect thereto
described in the Third Amendment and Consent to the Credit Agreement, dated January 20, 2004 shall have been consummated on the terms and conditions set forth therein. 

        11.    Affirmation of Obligations under the Loan Documents; No Waiver.    The Credit Parties hereby agree
(a) to continue to bound by all of the terms of the Loan Documents and all of the terms and conditions of the Loan Documents are hereby affirmed; (b) this Amendment shall not in any way
release or impair the rights, duties, Obligations or Liens created pursuant to the any Loan Document 

4

 

or
affect the relative priorities thereof, in each case to the extent in force and effect thereunder as of the date hereof and except as modified hereby, and all of such rights, duties, Obligations
and Liens are ratified and affirmed by each of the Credit Parties; (c) the execution, delivery and effectiveness of this Amendment shall not operate as a waiver of any right, power or remedy of
the Lenders or the Agent (as defined therein) under any Loan Document, nor constitute a waiver of any covenant, agreement or obligation under any Loan Document; (d) this Amendment shall not in
any way release or impair the rights, duties, Obligations or Liens created pursuant to the Collateral Documents (and such Liens shall continue without any diminution thereof and shall remain in full
force and effect on and after the date hereof) or affect the relative priorities thereof, in each case to the extent in force and effect thereunder as of the date hereof, and all of such rights,
duties, Obligations and Liens are ratified and affirmed by each Credit Party and the Liens granted pursuant to the Collateral Documents to which each of the Credit Parties is a party shall, except as
expressly provided herein, continue without any diminution thereof and shall remain in full force and effect on and after the date hereof; and (e) any and all references to the Collateral
Documents in any Loan Document shall, without further action of the parties, be deemed a reference to the Collateral Documents, as affirmed and modified by this Amendment, and as they may be further
amended, restated, supplemented or otherwise modified from time to time. 

        12.    Post-Closing Agreement.    The Credit Parties hereby agree that within 30 days after the
date hereof, Morpheus LLC shall enter into Collateral Documents separate from the US Credit Parties which reflect that they are only guaranteeing and providing security in support of the European
Obligations and the Credit Parties shall acknowledge that Morpheus LLC will no longer be a party to the existing Collateral Documents executed by the US Credit Parties. 

        13.    GOVERNING LAW.    THIS AMENDMENT SHALL BE GOVERNED BY, AND INTERPRETED IN ACCORDANCE WITH, THE LAW OF THE STATE
OF NEW YORK. 

        14.    Counterparts.    This Amendment may be executed by the parties hereto on any number of separate counterparts
and all of said counterparts taken together shall be deemed to constitute one and the same instrument. 

5

 

        IN
WITNESS WHEREOF, this Amendment has been duly executed as of the date first written above. 

	 	 	WAMPOLE LABORATORIES, LLC.

INVERNESS MEDICAL (UK) HOLDINGS LIMITED
	

 	
 	

By:	

/s/  ANTHONY J. BERNARDO      
 Name: Anthony J. Bernardo

Title: Duly Authorized Signatory

6

 

	 	 	AGENT AND LENDERS
	

 	
 	

GENERAL ELECTRIC CAPITAL

CORPORATION, as Agent and Lender
	

 	
 	

By:	

/s/  ILLEGIBLE      
 Duly Authorized Signatory
	

 	
 	

GENERAL ELECTRIC CAPITAL

CORPORATION, as Senior Agent
	

 	
 	

By:	

/s/  ILLEGIBLE      
 Duly Authorized Signatory
	

 	
 	

MERRILL LYNCH CAPITAL, a division of Merrill Lynch Business Financial Services Inc., as Co-Syndication Agent, Documentation Agent and Lender
	

 	
 	

By:	

/s/  ILLEGIBLE      
 Duly Authorized Signatory
	

 	
 	

UBS SECURITIES LLC, as Co-Syndication Agent
	

 	
 	

By:	

/s/  DAVID A. JUGE, MANAGING DIRECTOR      
 Duly Authorized Signatory
	

 	
 	

By:	

/s/  OLIVER O. TRUMBO II, DIRECTOR      
 Duly Authorized Signatory
	

 	
 	

UBS AG, CAYMAN ISLANDS BRANCH, as a Lender
	

 	
 	

By:	

/s/  WILFRED V. SAINT, ASSOCIATE DIRECTOR      
 Banking Products Services, US

Duly Authorized Signatory
	

 	
 	

By:	

/s/  THOMAS R. SALZANO, DIRECTOR      
 Banking Products Services, US

Duly Authorized Signatory

7

 

        The
following Persons are signatories to this Amendment in their capacity as Credit Parties, Grantors, Guarantors, Pledgors and not as Borrowers. 

	 	 	INVERNESS MEDICAL INNOVATIONS, INC.

INVERNESS MEDICAL, INC.

UNIPATH DIAGNOSTICS, INC.

UNIPATH ONLINE, INC.

OSTEX INTERNATIONAL, INC.

INVERNESS MEDICAL INTERNATIONAL

HOLDING CORP.

INVERNESS MEDICAL INTERNATIONAL

HOLDING CORP. II

UNIPATH LIMITED

APPLIED BIOTECH, INC.

FOREFRONT DIAGNOSTICS, INC.

MORPHEUS ACQUISITION CORP.

MORPHEUS ACQUISITION LLC

INVERNESS MEDICAL CANADA INC.—

MEDICALE INVERNESS CANADA INC.

INNOVATIONS RESEARCH LLC
	

 	
 	

By:	

/s/  ANTHONY J. BERNARDO      
 Name: Anthony J. Bernardo

Title: Duly Authorized Signatory
	

 	
 	

ORGENICS INTERNATIONAL HOLDINGS BV

INVERNESS MEDICAL SWITZERLAND GMBH

UNIPATH DIAGNOSTICS GMBH

CAMBRIDGE DIAGNOSTICS IRELAND LIMITED

PREGYMED GMBH

SCANDINAVIAN MICRO BIODEVICES APS
	

 	
 	

By:	

/s/  PAUL T. HEMPEL      
 Name: Paul T. Hempel

Title: Duly Authorized Signatory
	

 	
 	

SELFCARE TECHNOLOGY, INC.
	

 	
 	

By:	

/s/  DUANE L. JAMES      
 Name: Duane L. James

Title: Duly Authorized Signatory

8

QuickLinks

Exhibit 10.2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00066-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00066-of-00352.parquet"}]]